AUA 2017: Obesity was Associated with Improved Metastases-Free Survival after Surgery in 13,667 Prostate Cancer Patients

Boston, MA (UroToday.com) Metabolic syndrome, obesity, and diabetes mellitus have been established to exacerbate prostate cancer (PC), regardless of treatment or treatment modality. While associations between BMI and PC outcomes have been previously published in active surveillance PC patients, post-radical prostatectomy metastases free survival data is inconsistent. Within this context, Dr. Pierre Tenndstedt of the University Medical Center presents a single-institutions’ experience from 2004 through 2015.

13,667 patients with a median follow-up of 36.4 months post-RP were stratified into BMI strata, with obese status assigned to those with a BMI > 29. In multivariate analysis, obese patients were significantly less likely to experience subsequent metastases post-RP (HR: 0.7, 95% CI: 0.5-0.98, p=0.03). In propensity score matched analysis, obesity was also associated with a decreased risk of metastases. However, while obesity correlated with immediate risk of metastases following “curative” treatment, Dr. Tennstedt and colleagues did not find a statistically significant difference in prostate cancer specific survival in either the Kaplan-Meier or propensity score matched analysis.

While obesity was associated with increases in overall mortality and prostate cancer metastases, a causative relationship has not been established. Overall, the improved management of BMI, diabetes mellitus, and metabolic syndrome remain key points for potential healthcare reform.

Presented By: Pierre Tennstedt, Martini-Klinik at University Medical Center

Authors: Pierre Tennstedt, Georg Salomon, Derya Tilki, Lars Budäus, Raisa Pompe, Sami-Ramzi Leyh-Bannurah, Alexander Haese, Hans Heinzer, Hartwig Huland, Markus Graefen, Jonas Schiffmann

Written By: Linda Huynh (BS), an assistant research specialist from the University of California, Irvine, on behalf of UroToday.com

at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA